REVLIMID (Celgene Pty Ltd)
Product name
REVLIMID
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
162 working days (255)
Active ingredients
lenalidomide
Registration type
EOI
Indication
REVLIMID is now also indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.